#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3720	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2580	426.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	2002	2002	T	546	T	453	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3720	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2580	426.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1736	1736	C	557	C	447	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3720	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2580	426.6	0	HET	.	.	.	C388T	.	388	388	C	940	940	C	484	C,T	306,91	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6142	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3678	496.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1770	1770	A	532	A,C	431,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6142	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3678	496.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2404	2404	C	609	C,T,A	484,5,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6142	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3678	496.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2478	2478	A	614	A,C,T	498,4,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6142	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3678	496.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3030	3030	C	521	C	419	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	590	folP	855	855	100.0	folP.l15.c4.ctg.1	1733	100.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1175	1177	AGC	143;145;144	A;G;C,A	108;115;106,1	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_Z_01155	gyrA.WHO_Z_01155	1	1	27	1276	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3510	108.1	1	SNP	p	S91F	1	.	.	271	273	TTC	621	623	TTC	134;134;133	T;T;C	101;104;104	gyrA.WHO_Z_01155:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_Z_01155	gyrA.WHO_Z_01155	1	1	27	1276	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3510	108.1	1	SNP	p	D95N	1	.	.	283	285	AAC	633	635	AAC	134;133;134	A;A;C,A	104;106;109,1	gyrA.WHO_Z_01155:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_Z_01155	gyrA.WHO_Z_01155	1	1	27	1276	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3510	108.1	1	SNP	p	N95G	0	.	.	283	285	AAC	633	635	AAC	134;133;134	A;A;C,A	104;106;109,1	gyrA.WHO_Z_01155:1:1:N95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	562	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1721	97.8	1	SNP	p	G45D	0	.	.	133	135	GGC	684	686	GGC	169;169;170	G;G;C	139;140;139	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	298	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1137	76.9	0	.	n	.	0	A197.	DEL	197	197	A	700	700	A	145	A	108	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1282	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3220	118.5	1	SNP	p	D86N	1	D86N	NONSYN	256	258	GAC	726	728	AAC	150;151;152	A;A;C	116;118;123	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1282	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3220	118.5	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2256	2258	ATT	134;134;134	A;T,G;T	114;112,1;113	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1282	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3220	118.5	0	.	p	.	0	P720R	NONSYN	2158	2160	CCG	2628	2630	CGG	131;129;129	C;G;G	105;102;105	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1282	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3220	118.5	1	SNP	p	S87W	0	.	.	259	261	AGT	729	731	AGT	152;152;152	A,C;G;T	115,1;126;121	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1282	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3220	118.5	1	SNP	p	S87I	0	.	.	259	261	AGT	729	731	AGT	152;152;152	A,C;G;T	115,1;126;121	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1282	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3220	118.5	1	SNP	p	S87R	0	.	.	259	261	AGT	729	731	AGT	152;152;152	A,C;G;T	115,1;126;121	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1282	parC	2304	2304	99.78	parC.l15.c4.ctg.1	3220	118.5	1	SNP	p	S88P	0	.	.	262	264	TCC	732	734	TCC	153;153;154	T;C,T;C	123;121,1;123	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1010	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3149	96.1	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1580	1582	TGC	143;143;143	T,C,G;G,T;C	108,1,1;114,1;109	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1010	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3149	96.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1790	1792	GGC	157;152;153	G,C;G,T;C	125,1;119,1;122	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	906	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2713	99.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1378	1380	GCA	142;141;143	G;C;A	111;113;114	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	906	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2713	99.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1381	1383	ATC	144;143;144	A;T;C	115;108;114	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	906	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2713	99.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1393	1395	GTG	145;145;145	G;T;G,T,C	113;112;115,1,1	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	906	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2713	99.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1393	1395	GTG	145;145;145	G;T;G,T,C	113;112;115,1,1	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	906	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2713	99.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1897	1899	ACC	92;92;92	A;C;C,G	78;76;79,1	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	906	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2713	99.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1951	1953	GCG	96;97;98	G;C;G	72;71;72	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	906	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2713	99.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1951	1953	GCG	96;97;98	G;C;G	72;71;72	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	906	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2713	99.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2074	2076	GGC	114;114;114	G,A;G;C	95,1;99;98	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	906	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2713	99.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2083	2085	GGC	118;118;120	G;G;C	97;97;99	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	906	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2713	99.8	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2101	2103	TCG	120;120;119	T;C;G	96;100;95	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1366	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3435	118.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1802	1804	CCG	136;136;137	C;C;G	103;101;102	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	674	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2255	89.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	821	821	C	103	C	84	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	0	.	p	.	0	T26A	NONSYN	76	78	ACC	428	430	GCC	164;164;164	G;C;C	122;122;129	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	0	.	p	.	0	N38E	NONSYN	112	114	AAT	464	466	GAA	160;160;160	G;A;A,C	131;126;125,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	0	.	p	.	0	T87A	NONSYN	259	261	ACT	611	613	GCT	148;149;149	G;C,A;T	116;119,1;117	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	0	.	p	.	0	P175S	NONSYN	523	525	CCA	875	877	TCA	146;145;145	T;C,A;A	115;115,1;120	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	0	.	p	.	0	G189N	NONSYN	565	567	GGC	917	919	AAC	151;150;152	A;A;C	115;119;121	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	0	.	p	.	0	D212E	NONSYN	634	636	GAT	986	988	GAA	166;166;166	G;A;A,C	132;134;133,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	0	.	p	.	0	N213H	NONSYN	637	639	AAT	989	991	CAT	166;166;166	C;A;T,A	130;127;130,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	0	.	p	.	0	F215V	NONSYN	643	645	TTT	995	997	GTT	165;166;165	G,T;T;T	131,1;134;130	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	0	.	p	.	0	A218I	NONSYN	652	654	GCC	1004	1006	ATC	167;168;169	A,G;T,A,G;C	132,1;133,1,1;137	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	0	.	p	.	0	L221P	NONSYN	661	663	CTG	1013	1015	CCG	164;166;166	C;C;G	132;135;136	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1334	1336	GCA	175;176;172	G;C;A	146;142;141	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	1	SNP	p	G120K	1	.	.	358	360	AAG	710	712	AAG	146;148;151	A,C;A;G,T	116,1;117;113,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	1	SNP	p	A121D	1	.	.	361	363	GAC	713	715	GAC	152;152;153	G;A,C,T;C	118;120,2,1;123	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	784	porB1b	1047	1047	98.28	porB1b.l6.c17.ctg.1	1754	130.1	1	SNP	p	D121N	0	.	.	361	363	GAC	713	715	GAC	152;152;153	G;A,C,T;C	118;120,2,1;123	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2560	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5108	149.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2139	2141	CAT	150;147;147	C,A;A;T,A	120,1;119;121,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	406	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1221	98.7	1	SNP	p	V57M	1	.	.	169	171	ATG	619	621	ATG	188;188;187	A;T;G	139;143;142	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
